JP2000516913A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516913A5
JP2000516913A5 JP1998502318A JP50231898A JP2000516913A5 JP 2000516913 A5 JP2000516913 A5 JP 2000516913A5 JP 1998502318 A JP1998502318 A JP 1998502318A JP 50231898 A JP50231898 A JP 50231898A JP 2000516913 A5 JP2000516913 A5 JP 2000516913A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998502318A
Other languages
English (en)
Japanese (ja)
Other versions
JP4225572B2 (ja
JP2000516913A (ja
Filing date
Publication date
Priority claimed from DE19624659A external-priority patent/DE19624659A1/de
Application filed filed Critical
Publication of JP2000516913A publication Critical patent/JP2000516913A/ja
Publication of JP2000516913A5 publication Critical patent/JP2000516913A5/ja
Application granted granted Critical
Publication of JP4225572B2 publication Critical patent/JP4225572B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50231898A 1996-06-20 1997-06-20 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類 Expired - Fee Related JP4225572B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624659A DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624659.8 1996-06-20
PCT/EP1997/003245 WO1997048696A1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives

Publications (3)

Publication Number Publication Date
JP2000516913A JP2000516913A (ja) 2000-12-19
JP2000516913A5 true JP2000516913A5 (enExample) 2005-02-10
JP4225572B2 JP4225572B2 (ja) 2009-02-18

Family

ID=7797501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50231898A Expired - Fee Related JP4225572B2 (ja) 1996-06-20 1997-06-20 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類

Country Status (19)

Country Link
US (3) US7241745B2 (enExample)
EP (1) EP0923570B1 (enExample)
JP (1) JP4225572B2 (enExample)
CN (2) CN1152032C (enExample)
AT (1) ATE224888T1 (enExample)
AU (1) AU736206B2 (enExample)
BR (1) BR9709823B1 (enExample)
CA (1) CA2257448C (enExample)
CZ (1) CZ291791B6 (enExample)
DE (2) DE19624659A1 (enExample)
DK (1) DK0923570T3 (enExample)
ES (1) ES2179351T3 (enExample)
HU (1) HU225715B1 (enExample)
IL (1) IL127352A (enExample)
PT (1) PT923570E (enExample)
RU (1) RU2200734C2 (enExample)
TR (1) TR199802651T2 (enExample)
WO (1) WO1997048696A1 (enExample)
ZA (1) ZA975437B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
ES2230899T3 (es) * 1998-11-17 2005-05-01 F. Hoffmann-La Roche Ag Antagonistas iii receptores de 4-aroil-piperidin-ccr-3.
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6432432B1 (en) 1999-03-05 2002-08-13 Arch Chemicals, Inc. Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
HU230030B1 (hu) 1999-10-08 2015-05-28 Debiopharm International Sa Fab I inhibitorok
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
EP1560584B1 (en) 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US20110045065A1 (en) * 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
WO2009156421A1 (en) 2008-06-24 2009-12-30 Topotarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
WO2010130178A1 (zh) * 2009-05-12 2010-11-18 Sun Shuping 丙烯酰胺类衍生物及其制备药物的用途
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
EP2611804A1 (en) 2010-09-03 2013-07-10 Forma TM, LLC. Novel compounds and compositions for the inhibition of nampt
CN103270023B (zh) 2010-09-03 2016-11-02 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103189356B (zh) * 2010-09-29 2015-11-25 英特维特国际股份有限公司 N-杂芳基化合物
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
MX2013005479A (es) 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
RU2616612C2 (ru) * 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
MX347459B (es) 2011-05-09 2017-04-26 Forma Tm Llc Nuevos compuestos y composiciones para la inhibición de nampt.
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
PE20150224A1 (es) 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
AU2013279021C1 (en) 2012-06-19 2017-03-16 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
HK1215579A1 (zh) * 2012-11-29 2016-09-02 Karyopharm Therapeutics, Inc. 被取代的2，3-二氫苯並呋喃基化合物和其用途
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
DK3016946T3 (da) * 2013-07-03 2023-01-09 Karyopharm Therapeutics Inc Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
EP3055304A1 (en) * 2013-10-09 2016-08-17 Eli Lilly and Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
CA2954328A1 (en) 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
CN104447486B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 二烯氟代金刚烷类化合物、其制备方法和用途
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
CN104447483B (zh) * 2015-01-13 2016-07-27 佛山市赛维斯医药科技有限公司 含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
WO2017031323A1 (en) 2015-08-18 2017-02-23 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
TWI721016B (zh) * 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
EP3279192A1 (en) 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN107827897A (zh) * 2017-10-23 2018-03-23 青岛大学 一种手性七元螺环吲哚酮类化合物的合成方法
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
CN108558840B (zh) * 2018-06-04 2020-11-06 上海交通大学 水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
TN2021000159A1 (en) 2019-02-14 2023-04-04 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
SG11202113174SA (en) 2019-06-14 2021-12-30 Debiopharm Int Sa Medicament and use thereof for treating bacterial infections involving biofilm
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
JP2024518089A (ja) 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
US5326772A (en) 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0401256B1 (de) 1988-02-19 1993-05-26 Byk Gulden Lomberg Chemische Fabrik GmbH Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US5125957A (en) * 1989-11-01 1992-06-30 Sumitomo Chemical Company, Limited Pyrimidine derivatives
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
JPH05506027A (ja) 1990-04-10 1993-09-02 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピリジンエステル
US5352684A (en) 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
DE4020570A1 (de) 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
US5244908A (en) 1990-07-30 1993-09-14 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their pharmaceutical use
EP0479601B1 (en) 1990-10-05 1999-12-15 Ajinomoto Co., Inc. Piperidine derivatives and their use as antiarrhythmic agents
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5246948A (en) 1991-05-10 1993-09-21 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
EP0548883A1 (de) 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
WO1994001402A1 (en) 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL111257A0 (en) 1993-10-15 1994-12-29 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2174105C (en) 1993-10-15 2002-02-12 W. Robert Bishop Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU698313B2 (en) 1994-03-14 1998-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide

Similar Documents

Publication Publication Date Title
JP2000514937A5 (enExample)
JP2001503577A5 (enExample)
JP2000501771A5 (enExample)
JP2000515083A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000508322A5 (enExample)
JP2000501324A5 (enExample)
JP2000517051A5 (enExample)
JP2000516913A5 (enExample)
JP2000500055A5 (enExample)
JP2001503233A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000515866A5 (enExample)
JP2000500912A5 (enExample)
JP2000506032A5 (enExample)
JP2000502570A5 (enExample)
JP2000514346A5 (enExample)
JP2001502260A5 (enExample)
JP2000505684A5 (enExample)